Quantcast

Latest CancerVax Stories

2010-02-04 07:01:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE®...

2009-12-08 09:00:00

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were...

2009-12-07 06:00:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana....

2009-12-02 06:00:00

BETHESDA, Md., Dec. 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast and conference call on, Tuesday, December 8, 2009, at 12:00 pm Eastern Time (6:00 pm Central European Time) to discuss the blinatumomab data that was presented at the American Society of Hematology (ASH) meeting. To access the webcast...

2009-12-01 05:00:00

BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors. Under the terms of the agreement, Bayer Schering Pharma...

2009-11-30 06:00:00

BETHESDA, Md., Nov. 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana. Results from the completed phase 2 clinical trial with blinatumomab...

2009-11-24 05:30:00

NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., (Nasdaq: DCTH) a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies...

2009-11-03 10:00:00

Patient advocacy group, research community and pharmaceutical companies join forces for new breakthroughs in treatment; clinical trials to begin in 2010 HILLSBOROUGH, N.J., Nov. 3 /PRNewswire-USNewswire/ -- For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel...

2009-10-21 09:30:00

BETHESDA, Md., Oct. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its Senior Vice President and Chief Financial Officer, Barclay Phillips, will present at The 8th Annual BIO Investor Forum on October 29, 2009 in San Francisco. A simultaneous webcast of the event will be available on the company's website at...

2009-10-20 14:55:00

DETROIT, Oct. 20 /PRNewswire-USNewswire/ -- Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment. Dr. Poojary's grant brings the total number of federal stimulus grant dollars received by Karmanos researchers to approximately $8 million this...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related